Vestcor Inc lessened its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 43.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,100 shares of the company's stock after selling 10,100 shares during the quarter. Vestcor Inc's holdings in AstraZeneca were worth $1,021,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Diversified Trust Co lifted its stake in AstraZeneca by 22.7% in the second quarter. Diversified Trust Co now owns 5,330 shares of the company's stock valued at $416,000 after buying an additional 987 shares during the period. SteelPeak Wealth LLC bought a new stake in AstraZeneca in the second quarter valued at approximately $211,000. Assenagon Asset Management S.A. raised its holdings in AstraZeneca by 106.5% in the second quarter. Assenagon Asset Management S.A. now owns 533,327 shares of the company's stock worth $41,594,000 after purchasing an additional 275,023 shares during the period. Miracle Mile Advisors LLC boosted its position in shares of AstraZeneca by 9.3% during the second quarter. Miracle Mile Advisors LLC now owns 8,325 shares of the company's stock worth $649,000 after purchasing an additional 711 shares in the last quarter. Finally, Portside Wealth Group LLC grew its holdings in shares of AstraZeneca by 19.1% in the 2nd quarter. Portside Wealth Group LLC now owns 6,731 shares of the company's stock valued at $525,000 after buying an additional 1,080 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.
AstraZeneca Stock Performance
Shares of AZN traded down $0.36 during mid-day trading on Friday, hitting $66.58. 6,538,059 shares of the company's stock were exchanged, compared to its average volume of 5,319,761. The firm has a market cap of $206.44 billion, a price-to-earnings ratio of 31.86, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock's 50-day simple moving average is $70.18 and its 200-day simple moving average is $76.71.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business's quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the firm earned $0.87 EPS. On average, equities research analysts expect that AstraZeneca PLC will post 4.11 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Finally, Erste Group Bank raised AstraZeneca from a "hold" rating to a "buy" rating in a research note on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $89.75.
Get Our Latest Stock Analysis on AZN
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
